The Body Pharm NAD+ 1000 Pen is a high-payload NAD+ subcutaneous pen available to South African researchers: 1000mg of nicotinamide adenine dinucleotide (NAD+) in a sterile multi-dose injection pen.
Body Pharm NAD+ 1000 Pen at a Glance
- 1000mg payload β double the coenzyme per pen versus 500mg alternatives, giving wider dose-range flexibility for in vitro protocols.
- Multi-dose pen format β adjustable dosing dial, pre-filled cartridge, no mixing required.
- Body Pharm manufacture β supplied through JCSG.org with local South African dispatch.
| Specification | Detail |
|---|---|
| Active compound | Nicotinamide adenine dinucleotide (NAD+) |
| Dose per pen | 1000mg |
| Delivery | Subcutaneous injection pen, pre-filled cartridge, adjustable dosing dial |
| Manufacturer | Body Pharm |
| Classification (SA) | Research chemical, laboratory/in vitro use only |
| Excipients disclosed | Not publicly specified; sterile aqueous solution |
For mechanism background on how NAD+ functions as a coenzyme in redox and sirtuin signalling pathways, see the NAD+ overview. Researchers working on adjacent mitochondrial pathways may also reference the MOTS-C research peptide page for comparative cellular energy work.
What is the Body Pharm NAD+ 1000 Pen?
The Body Pharm NAD+ 1000 Pen is a 1000mg nicotinamide adenine dinucleotide (NAD+) solution housed in a multi-dose subcutaneous injection pen, manufactured by Body Pharm and sold in South Africa as a research chemical for in vitro and laboratory use.
| Specification | Value |
|---|---|
| Active compound | Nicotinamide adenine dinucleotide (NAD+) |
| Concentration | 1000mg per pen |
| Delivery format | Subcutaneous multi-dose injection pen |
| Manufacturer | Body Pharm |
| Classification | Research chemical, not for human consumption |
| Excipients / buffer | Not publicly specified (sterile aqueous solution) |
| Storage temperature | Not publicly specified by vendor |
| Shelf life | Not publicly specified by vendor |
| Third-party CoA | Request from supplier before purchase |
For mechanism context on the active compound, see the NAD+ overview. Researchers comparing mitochondrial and cellular-energy targets alongside NAD+ may also reference the MOTS-C research peptide category for adjacent procurement decisions.
NAD+ and Cellular Energy: The Research Basis
NAD+ is a redox coenzyme required for mitochondrial oxidative phosphorylation and ATP production. It accepts and donates electrons in the electron transport chain and is the obligate substrate for the sirtuin family (SIRT1βSIRT7) in DNA repair and metabolic signalling. These enzymes cannot function without it as a cofactor.
Tissue NAD+ pools decline with age in mammals. Gomes et al. (Cell Metabolism, 2013) linked that decline to pseudohypoxic mitochondrial dysfunction in aged mice, which anchored the modern NAD+ longevity hypothesis.
Where the human evidence sits in 2026
Human longevity outcomes from NAD+ precursor supplementation remain an active area of research. Most trials have measured blood NAD+ metabolites rather than clinical endpoints. Several NMN and NR randomised trials published between 2023 and 2025 raised blood NAD+ metabolites reliably while producing varied results on primary clinical endpoints β insulin sensitivity in prediabetes cohorts, carotid intima-media thickness and VO2max in cardiovascular-risk adults, and walking-speed performance in sarcopenia cohorts.
No peer-reviewed 2023β2025 human trial directly compares subcutaneous NAD+ delivery against oral NMN or NR pharmacokinetics in the same cohort. The bioavailability advantage of injection remains mechanistically well-founded but not yet fully benchmarked against oral routes in head-to-head human studies.
| Mechanistic element | Established role | 2026 evidence status |
|---|---|---|
| NAD+ in oxidative phosphorylation | Electron carrier (NAD+/NADH) in ETC complex I | Established biochemistry |
| Sirtuin activation (SIRT1βSIRT7) | NAD+ consumed as substrate for deacetylation, DNA repair | Established at molecular level |
| Age-related NAD+ decline | Documented in mammalian tissues (Gomes 2013) | Foundational |
| Oral NMN/NR clinical endpoints | Raises blood NAD+ metabolites | Active research area, 2023β2025 |
| Subcutaneous NAD+ vs oral precursor PK | No direct head-to-head human trial identified | Emerging gap |
For adjacent mitochondrial-energy pathways outside the NAD+/sirtuin axis, the MOTS-C research peptide page covers a separate mitochondria-derived signalling target relevant to comparative in vitro work.
Subcutaneous vs Oral NAD+ Delivery
Subcutaneous NAD+ delivery bypasses first-pass hepatic metabolism and gut absorption variability. The injection deposits the compound directly into interstitial tissue, allowing diffusion into capillary and lymphatic circulation without portal-vein passage. Oral NMN and NR require enzymatic conversion to NAD+ before reaching systemic circulation, which introduces multiple rate-limiting steps.
For researchers procuring a NAD+ 1000mg pen, this pharmacokinetic distinction is the primary mechanistic reason injectable formats are used over capsules for in vitro or laboratory work where dose predictability matters.
Oral NMN must transit the gut wall. Slc12a8 transporter activity and microbial degradation introduce inter-individual variability before hepatic conversion via NMNAT enzymes yields NAD+. Oral NR follows a parallel pathway through nicotinamide riboside kinases (NRK1/NRK2) and NMN intermediates. Both routes are rate-limited and produce wide plasma NAD+ metabolite ranges across cohorts in 2023β2025 trials.
Delivery route comparison for research use
| Route | Onset | First-pass bypass | Repeated-dose practicality |
|---|---|---|---|
| Oral NMN / NR | Slow (hours) | No | High (capsule) |
| Subcutaneous NAD+ pen | Moderate (30β90 min, inferred) | Yes | High (self-administered pen) |
| IV NAD+ infusion | Fast (minutes) | Yes | Low (clinical setting only) |
The Body Pharm NAD+ 1000 Pen delivers the subcutaneous advantage in a multi-dose format suited to serial dosing schedules without clinical infrastructure.
Background on the broader pathway and adjacent targets sits on the NAD+ overview page.
Regulatory Framing in South Africa: Research Use Only
Injectable NAD+ pens are marketed in South Africa under a "research use only / not for human consumption" classification. SAHPRA is the South African Health Products Regulatory Authority, responsible for assigning Schedules 0β7 to medicines and health products. No 2022β2024 SAHPRA scheduling communiquΓ© in the public record names injectable NAD+ or nicotinamide adenine dinucleotide explicitly.
What "research use only" means
The label removes any therapeutic, diagnostic, or curative claim from the product. This is the legal mechanism by which vendors avoid presenting the pen as a medicine. The current regulatory status of the NAD+ 1000mg pen category should be confirmed with SAHPRA directly for institutional procurement decisions.
Practical procurement checklist
Before procuring the Body Pharm NAD+ 1000 Pen, or adjacent compounds such as the MOTS-C research peptide:
- Confirm current SAHPRA schedule classification for injectable NAD+ at the date of order.
- Obtain vendor's written acknowledgement of the "not for human consumption" classification on the invoice.
- Check whether your institution requires ethics or biosafety clearance for in vitro work with the compound.
- Confirm cold-chain and customs handling terms for any cross-border shipment.
For mechanism background separate from regulatory framing, see the NAD+ overview. Nothing in this section constitutes legal or medical advice.
Formulation and Purity: What to Request
The Body Pharm NAD+ 1000 Pen is listed with the active compound and dose. As with all research chemical procurement, best practice is to request a batch-numbered certificate of analysis (CoA) covering:
- Identity by HPLC chromatogram
- Purity percentage
- Microbial and endotoxin testing results
Request the CoA in writing from the supplier before dispatch where one is not already published.
Related Research Peptides for Longevity Studies
Researchers procuring the NAD+ 1000mg pen often run parallel procurement on adjacent peptides studied in mitochondrial-energy and cellular-repair contexts. All compounds below are classified as research chemicals for in vitro or laboratory use only.
| Peptide | Research context | Mechanism category |
|---|---|---|
| NAD+ | Cellular redox, sirtuin cofactor research | Coenzyme |
| MOTS-C | Mitochondria-derived peptide, metabolic regulation research | Mitochondrial-encoded peptide |
| GHK-Cu | Cellular repair signalling, extracellular matrix research | Copper-binding tripeptide |
| CJC-1295 | Growth hormone axis, ageing-related endocrine research | GHRH analogue |
Adjacent procurement decisions
MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region, studied in metabolic regulation models because mitochondria release it under metabolic stress. GHK-Cu is a copper-binding tripeptide investigated for fibroblast signalling and extracellular matrix turnover. CJC-1295 is a growth hormone-releasing hormone analogue studied in endocrine ageing models because GH secretion declines with age.
Frequently Asked Questions
Why does the 1000mg dosage matter versus a 500mg pen?
A 1000mg NAD+ pen delivers double the coenzyme payload per device versus a 500mg pen. This matters for in vitro dose-response protocols where researchers titrate across concentration ranges β wider dose spacing reduces the number of pens required.
Is subcutaneous NAD+ better than oral NMN for research purposes?
No peer-reviewed human trial published between 2023 and 2025 directly compares subcutaneous NAD+ pen delivery against oral NMN or NR for bioavailability in the same cohort. The mechanistic rationale for subcutaneous delivery β bypassing first-pass hepatic metabolism β is well-established, which is why the pen format is used in precision in vitro dosing protocols.
Are NAD+ pens legal in South Africa?
Regulatory status requires confirmation with SAHPRA. No specific Schedule (0β7) entry names injectable NAD+ as of 2026. The "research use only" classification is vendor-applied. Researchers should obtain written regulatory advice before assuming these products are unscheduled.
How do I verify the purity of a NAD+ pen?
Request a batch-specific certificate of analysis (CoA) directly from JCSG.org when placing your order. It should include an HPLC chromatogram, microbial testing, and endotoxin results. Cross-reference batch numbers against any third-party lab report supplied.
Where can I buy the Body Pharm NAD+ 1000 Pen in South Africa?
The pen is available through JCSG.org with local South African dispatch. The current ZAR price is shown in the buy box on this page.
Further Reading
For mechanism background, start with the NAD+ overview. For adjacent panel procurement, explore the MOTS-C research peptide or browse all research peptides.
This product is sold for in vitro research and laboratory use only. Not for human consumption.
